To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:3 Issue:3 Number:3 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
Author Verified
Meta-Analysis
ACE Report #4681
Ace Report Cover General Orthopaedics

Etidronate, alendronate, and reisendronate significantly reduce the risk of hip fracture


How to Cite

OrthoEvidence. Etidronate, alendronate, and reisendronate significantly reduce the risk of hip fracture. ACE Report. 2014;3(3):3. Available from: https://myorthoevidence.com/AceReport/Report/4681

Study Type:Meta analysis
OE Level Evidence:2
Journal Level of Evidence:N/A

Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: a meta-analysis of randomized controlled trials among the Japanese population

Curr Med Res Opin. 2011 Jun;27(6):1141-8. doi: 10.1185/03007995.2011.570747. Epub 2011 Apr 1

Contributing Authors:
J Iwamoto T Takeda H Matsumoto

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Seven randomized controlled trials were included in this meta-analysis which investigated the use of oral bisphosphonates (etidronate, alendronate, or risendronate) in the prevention of hip fracture in the population suffering from neurological diseases, such as amylotrophic lateral sclerosis, stroke, or Parkinson's disease. Included studies were placebo controlled with the exception of one, which...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.